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Sleep disturbances are highly prevalent in affective disor-
ders ( Asaad et al., 2016; Bradley et al., 2017 ). In bipolar
disorder (BD) they may occur in 30–60% of patients, but re-
ported rates vary from 10% to 80% depending on definition
and management of potential confounding factors such as
pharmacological treatments ( Steinan et al., 2016a; 2016b ).
Sleep disturbances have been increasingly recognized as im-
portant predictors of relapse in both major depressive dis-
order (MDD) and BD ( Bao et al., 2017; Bromberger et al.,
2016; Craig et al., 2000; Gershon et al., 2017; Sakurai et
al., 2017 ). Most descriptive studies on depressed or BD sub-
jects with sleep alterations have focused on insomnia or de-
creased need to sleep, while fewer studies explored the
presence of hypersomnia and its associated clinical fea-
tures, despite its reported prevalence in 17–78% of patients
with BD depression ( Steinan et al., 2016b ). 
Recent data on theoretical models of BD supported the
hypothesis that sleep disturbances may be a marker of un-
derlying global circadian dysregulation ( Kapczinski et al.,
2011; Rosa et al., 2013 ), including unfavorable rapid cy-
cling course or mood instability ( Mosolov, 1996; Strejile-
vich et al., 2013 ) and involving other parameters like the
body mass index (BMI) ( Samalin et al., 2017; Steinan et al.,
2016a ). Specifically, a Delayed Sleep Phase (DSP), defined
as sleep onset insomnia and/or morning sleepiness that may
extend for 3–6 h, was present in 10% of a sample of 404
BD patients and associated to a higher mean BMI ( Steinan
et al., 2016b ). In a cross-sectional study higher BMI in BD
but not healthy controls significantly correlated with lower
sleep efficiency, shorter total sleep time, longer sleep onsetPlease cite this article as: A. Murru, G. Guiso and M. Barbuti et al., The
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02.011 tion in the need for sleep” is the only sleep-related criteria for
pisodes. We aimed at studying the prevalence, clinical corre-
ia in a sample of acutely depressed patients. Secondarily, we
the odds of hypersomnia were studied. We conducted a post-
 study. Variables were compared between patients with hyper-
nia (SLEEP −) with standard bivariate tests. A stepwise back-
was performed with SLEEP + as dependent variable. A total of
d into SLEEP + ( n = 423, 16.8%) and SLEEP − ( n = 2091, 83.2%).
tes of obese BMI ( p < 0.001), BD diagnosis ( p = 0.027), severe
 attempts ( p < 0.001), lower age at first depression ( p = 0.004)
 significantly poorer response to antidepressants (AD) such as
ance, affective lability, or irritability (all 0 < 0.005). Moreover,
ates of mixed-state specifiers than SLEEP- (all 0 < 0.006). A sig-
mnia in our regression model was driven by metabolic-related
mia” (OR = 4.21) and “overweight/obese BMI (OR = 1.42)”.
ated with poor outcome in acute depression. Hypersomnia is
features and bipolarity. Metabolic aspects could influence the
sening the overall clinical outcome. Along with commonly used
persomnia has potential, costless discriminative validity in the
nd bipolar depression. 
ll rights reserved. 
latency, higher fragmentation index, higher inter-day vari-
ability ( Boudebesse et al., 2015 ). 
A relationship between depression, especially with atyp-
ical features, and obesity has been widely demonstrated
( Chou and Yu, 2013; de Wit et al., 2010; Lasserre et al.,
2014; Luppino et al., 2010 ) but the nature of this associa-
tion still remains unclear. Atypical symptoms, which include
hypersomnia, in depressed patients have been associated
with both obesity and bipolarity ( Forty et al., 2008; Łojko
et al., 2015 ). Likewise, excess bodyweight and obesity are
highly prevalent in individuals with BD and this association
is considered as one of many comorbidities generating con-
cern in BD populations due to important health implications
( Liu et al., 2013 ). Unfortunately, the direction of this asso-
ciation is not clear. In fact, obese patients show a higher
risk of developing major MDD and BD ( Simon et al., 2006 ),
but the course of bipolar depression is also frequently af-
fected by the development of overweigh and obesity, pos-
sibly related to the effects of psychotropic medications or
to comorbid diagnoses with eating disorders, such as binge
eating disorder (BED). Notwithstanding, this association un-
derpins genetic and neurobiological liability ( McElroy et al.,
2018, 2013, 2011 ; McElroy and Keck, 2014 ). In BD, obesity is
directly associated with a worse illness course and outcome,
including increased suicidality and decreased cognitive per-
formance ( Fagiolini et al., 2004; Yim et al., 2012 ). Metabolic
comorbidity in BD may also act as a “mood destabilizer”,
increasing depressive symptom severity and recurrence ( Liu
et al., 2013 ). A recent post-hoc analysis of the Bipolar Disor-
ders: Improving Diagnosis, Guidance and Education (BRIDGE-
II-MIX) naturalistic study ( Perugi et al., 2016 ; 2015; Popovic
et al., 2015 ) assessed the association between obesity and implications of hypersomnia in the context of major depression: 
psychopharmacology, https://doi.org/10.1016/j.euroneuro.2019. 
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2  he presence of bipolar features, concluding that higher BMI 
n patients with major depression (MDE) seems to be associ- 
ted with a lifetime diagnosis of BD and with a poorer illness
utcome and suggesting that obesity in patients with MDE 
ould be considered a possible marker of bipolarity ( Petri et
l., 2017 ). 
The objective of the present post-hoc analysis was to as- 
ess possible diagnostic and clinical correlates of insomnia 
SLEEP −) or hypersomnia (SLEEP + ) in the population re-
ruited for the BRIDGE-II-Mix study. Secondarily, a statis- 
ical model predicting the likelihood of hypersomnia was 
erformed, as well as a statistical model to understand 
hether the presence of combined hypersomnia and over- 
eight/obesity phenotype could define a subgroup of pa- 
ients with specific clinical features. 
. Methods 
.1. Study population recruitment 
his study is a post-hoc analysis of the BRIDGE-II-Mix study ( Perugi
t al., 2015 ). The primary objective of BRIDGE-II-MIX naturalistic
tudy was to provide a reliable estimate of the frequency of mixed
tates in a large international sample of patients diagnosed with
DE according to several sets of criteria. The BRIDGE-II-Mix Study
as a multisite, international, non-interventional, cross-sectional 
tudy. The recruitment procedure and the inclusion criteria have 
een described in a previous study ( Popovic et al., 2015 ). From an
nitial pool of 2811 patients with MDE, sleep disturbances were de-
ected in 2514 patients who were thus included in the present post-
oc analysis. 
.2. Data collection 
n a single consultation the participating psychiatrists completed a 
ase report form for each patient, incorporating inclusion criteria, 
ocio-demographic variables (age, gender and marital status), bio- 
etrics values (height and weight), in- or out-patient status, his-
ory of psychiatric symptoms (mood symptoms, suicide attempts) 
nd previous psychiatric hospitalizations. Features of the MDE, in- 
luding bipolar symptoms listed in the DSM-IV-TR diagnostic criteria 
or BD, known risk factors for BD (e.g. family history of BD, early
nset depression), previous response to ADs, psychiatric comorbid- 
ty, current treatment and functional status determined by the in-
estigator using the Global Assessment of Functioning (GAF) were 
ssessed ( Endicott et al., 1976 ). 
The evaluation packet was explicitly structured to use skills that
ully trained psychiatrists would have and routinely apply in con-
ucting an initial evaluation of an acutely ill patient. No rating
cales requiring calibration with a standard were incorporated. 
aters were instructed to follow their usual practice, as training
ight have altered these practices and might be seen as a biasing
actor. 
The primary objective of the BRIDGE-II-MIX study was to estab-
ish the frequency of depressive mixed states by analyzing all the
elevant symptoms of either pole. After the publication of DSM-5,
his was post-hoc defined as (1) the proportion of patients fulfilling
SM-5 criteria for MDE with mixed features ( American Psychiatric
ssociation, 2013 ), and (2) research based diagnostic criteria for
ixed states (RDC). RDC are defined by the presence of MDE plus
 out of the following 14 hypomanic symptoms for at least a week:
rritable mood, affective lability, distractibility, psychomotor agi- 
ation, impulsivity, aggression (verbal or physical), racing thoughts, Please cite this article as: A. Murru, G. Guiso and M. Barbuti et al., The
Results from a large, international, observational study, European Neuro
02.011 ore talkative/pressure to keep talking, hyperactivity, increased 
nergy, risky behavior, grandiosity, elation, hyper-sexuality. The 
roportion of patients fulfilling criteria for BD according to the DSM-
V-TR and bipolarity specifier proposed by Angst et al. ( 2005; 2011;
013 ) was also identified. The bipolarity specifier attributes a di-
gnosis of BD to patients who experienced an episode of elevated
ood or irritable mood or increased activity with at least three
f the symptoms listed under Criterion B of the DSM-IV-TR, asso-
iated with at least one of the three following consequences: (i)
nequivocal and observable change in functioning uncharacteris- 
ic of the person’s usual behavior, (ii) marked impairment in social
r occupational functioning observable by others or (iii) requiring
ospitalization or outpatient treatment. No minimum duration was 
equired and no exclusion criteria were applied. 
.3. Ethical aspects 
n each participating country, the study protocol was approved by
he local ethics committee, in accordance with the Declaration of
elsinki. Each patient provided written informed consent in order
o participate. 
.4. Statistical analyses 
he sample was dichotomized into patients reporting reduced sleep
SLEEP-) and increased sleep (SLEEP + ). Variables were compared
etween the 2 study subgroups with Chi-square (categorical vari-
bles) and Student’s t -test (continuous variables). A stepwise back-
ard logistic regression model was then used to identify the likeli-
ood of selected variables in predicting insomnia versus hypersom-
ia. The stepwise modeling procedure started with the full model
nd consisted, for each step, in eliminating the least statistically
ignificant variable from the model and re-computing the revised
odel, until all remaining variables were at p < 0.1. Statistical
nalyses were performed using the Statistical Package for Social
ciences (Statistical Package for Social Science-SPSS, 23.0 version
or Windows Inc., Chicago, IL, USA). All p values were two-tailed
nd statistical significance was set at p < 0.05. 
. Results 
 total of 2514 depressed individuals were derived from
he original BRIDGE-II-MIX sample and considered in the 
resent post-hoc analysis. The sample was dichotomized 
nto SLEEP − ( n = 2091, 83.2%) and SLEEP + ( n = 423, 16.8%)
ubgroups, based on the presentation of objective reduction 
f sleep or hypersomnia respectively. 
When considering sociodemographic and lifestyle char- 
cteristics of the sample, SLEEP + patients showed signifi-
ant higher rates of single marital status (29.3% vs. 22.9%,
 = 0.006) and obese BMI (23.0% vs. 15.4%, p < 0.001), sig-
ificant less normal BMI (47.1% vs. 37.1%, p < 0.001) than
LEEP–. No differences were found in sex distribution or age
t evaluation (see Table 1 ). 
When considering characteristics related to current di- 
gnosis and possible past course of illness, SLEEP + sub-
roup showed significant higher rates of BD diagnosis (20.6%
s. 16.0%, p = 0.027), a more severe course of BD ill-
ess measured with CGI (2.80 ± 1.72 vs. 2.26 ± 1.68,
 < 0.001), higher rates of atypical features (32.2% vs.
.8%, p < 0.001) and lifetime suicide attempts (29.3% vs.
1.0%, p < 0.001), significant lower rates of MDD (79.4% vs. implications of hypersomnia in the context of major depression: 
psychopharmacology, https://doi.org/10.1016/j.euroneuro.2019. 
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Table 1 Sociodemographic and lifestyle characteristics of the included sample ( n = 2514). 
Sleep − ( n = 2091) Sleep + ( n = 423) 
Variables (YES) n % n % χ2 p 
Sex (female) 1430 68.4 305 72.1 2.271 0.132 
Marital status 
Married 1153 55.1 220 52.0 1.392 0.238 
Divorced 336 16.1 63 14.9 0.364 0.546 
Single 479 22.9 124 29.3 7.891 0.006 
Current smoker 725 34.7 158 37.4 1.109 0.292 
BMI 
Underweight 77 3.8 22 5.3 2.145 0.143 
Normal 961 47.1 155 37.1 12.369 < 0.001 
Overweight 688 33.7 145 34.7 0.301 0.610 
Obese 314 15.4 96 23.0 15.197 < 0.001 
Variable Mean SD Mean SD F p 
Age 43.96 13.80 41.08 13.03 3.953 < 0.001 











































































84.0, p < 0.001), also at first episode (18.0% vs. 26.0,
p = 0.027) than SLEEP-. SLEEP + also showed significant
lower age at first psychiatric symptoms (29.14 ± 12.19 vs.
33.38 ± 12.93, p = 0.012) and age at first depression on-
set (32.55 ± 11.75 vs. 35.93 ± 12.68, p = 0.004) than
SLEEP-. When considering past episodes, SLEEP + pa-
tients showed a significantly higher number of depres-
sions (5.71 ± 6.99 vs. 4.48 ± 5.78, p < 0.001) and sui-
cide attempts (1.52 ± 3.01 vs. 0.41 ± 3.98, p = 0.031), last
year’s overall number of mood episodes (2.99 ± 6.66 vs.
2.12 ± 3.94, p < 0.001), total days spent depressed
(120.00 ± 96.00 vs. 107.94 ± 96.14, p = 0.016) and to-
tal days spent (hypo)manic 20.21 ±43.57 vs. 12.24 ± 39.94,
p < 0.001) than SLEEP − patients (see Table 2 ). 
SLEEP + patients presented significantly higher rates of
mixed-state according to RDC (32.9% vs. 27.6%, p = 0.029),
but not to DSM-5 specifier (5.0% vs. 8.3%, p = 0.021).
When considering each RDC mixed symptom, SLEEP + pre-
sented more frequently racing thoughts, (15.1% vs. 10.6%,
p = 0.007), affective lability (37.6% vs. 27.5%, p < 0.001),
distractibility (29.6% vs. 23.4%, p = 0.007), impulsivity
(16.8% vs. 13.2%, p = 0.048), hypersexuality (4.0% vs. 2.3%,
p = 0.042) than SLEEP-, and significantly less risky behavior
(5.0% vs. 7.8%, p = 0.041). 
Past treatments with antidepressants (AD) were statisti-
cally more frequent in SLEEP + patients (85.3% vs. 79.5%,
p = 0.006), and this subgroup of patients also presented
significant higher rates in all variables related to poor re-
sponse to AD, such as reporting (hypo)manic switches (24.1%
vs. 15.3%, p < 0.001), resistance to AD treatment (34.3%
vs. 27.1%, p = 0.003), affective lability (41.6% vs. 26.7%,
p = 0.001) or irritability (33.1% vs. 24.8%, p < 0.001) (see
Table 3 ). 
SLEEP + patients presented frequent comorbidities with
other psychiatric conditions, statistically significant com-
pared to SLEEP- for obsessive–compulsive disorder (OCD,
7.6% vs. 4.2%, p = 0.002), social phobia (13.5% vs. 6.4%,
p < 0.001), generalized anxiety disorder (GAD, 23.2% vs.
17.2%, p = 0.003), binge eating syndrome (13.7% vs. 6.0%,
p < 0.001), bulimia (6.1% vs. 1.0%, p < 0.001), night eat-
ing syndrome (5.5% vs. 2.2%, p < = 0.001). Atypical antipsy-Please cite this article as: A. Murru, G. Guiso and M. Barbuti et al., The
Results from a large, international, observational study, European Neuro
02.011 chotics (34.0% vs. 22.1%, p < 0.001) and mood stabilizers
(40.0% vs. 26.0, p < 0.001) were significantly more fre-
quently used in SLEEP + group (see Table 4 ). 
Stepwise backward logistic regression was performed to
assess the impact of 25 factors on the likelihood that pa-
tients would report a problem of hypersomnia. 
The full model as a whole was significant, χ2 (12,
N = 2461) = 153.392, p < 0.001. A total of 11 independent
variables made a unique statistically significant contribution
to the model, here presented in order of strength in pre-
dicting hypersomnia: “current bulimia” (OR = 4.21), “cur-
rent social phobia” (OR = 1.77), “overweight/obese BMI
(OR = 1.42)”, “affective lability with previous AD treatment”
(OR = 1.37), “affective lability” (OR = 1.37), “treatment
with atypical antipsychotics (OR = 1.36), “treatment with
mood stabilizers” (OR = 1.33), “lifetime suicide attempts
(OR = 1.31), “number of days depressed in the last year”
(OR = 1.00), “age at first depression” (OR = 0.98)“risky be-
havior symptoms” (OR = 0.32) (see Table 5 ). 
We decided to consider dichotomized BMIs subgroups,
by dividing the sample in “patients with BMI above nor-
mal and “patients with BMI of normal value or be-
low”. Sleep subgroups still differed statistically, as SLEEP +
(241, 57.0%) were more frequently overweight/obese than
SLEEP − (1002, 47.9%, χ2 11.539, p = 0.001). Given the con-
sistent contribution of metabolic-related variables in pre-
dicting the model of hypersomnia, we conducted a sec-
ondary analysis on the patients with both hypersomnia and
BMI above normal in order to define this more extreme,
“atypical” phenotype. These patients presented themselves
as a more extreme phenotype with respect to the SLEEP +
subgroup (see Supplementary Material Table S1). A simi-
lar comparison between this atypical profile and the oppo-
site phenotype (sleep reduction/BMI below normal) showed
again the clinical distance between these clinical pheno-
types (see Supplementary Material Table S2). The step-
wise backward logistic regression conducted on the ex-
treme phenotype was also overall significant (7, N = 2478,
χ2 = 98.868, p < 0.0005), with significant contribution
made by current bulimia (OR = 3.99), current binge eat-
ing (OR = 2.30), current social phobia (OR = 1.65), current implications of hypersomnia in the context of major depression: 
psychopharmacology, https://doi.org/10.1016/j.euroneuro.2019. 
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Table 2 Diagnostic and past course of illness characteristics of the included sample. 
Sleep − ( n = 2091) Sleep + ( n = 423) 
Variables (YES) n % n % χ2 p 
Diagnosis 
BD Diagnosis 
Total 334 16.0 87 20.6 5.326 0.027 
BD type I 206 9.9 54 12.8 3.222 0.080 
BD type II 128 6.1 33 7.8 1.657 0.198 
UMD 1757 84.0 336 79.4 5.326 0.027 
First Episode 543 26.0 76 18.0 12.137 < 0.001 
Clinical features 
Presence of fatigue/energy loss 1960 93.9 412 97.4 8.381 0.004 
Atypical features 37 1.8 136 32.2 506.803 < 0.001 
Lifetime suicide 439 21.0 124 29.3 14.012 < 0.001 
Illness onset Mean SD Mean SD F p 
Age at 1st symptoms 33.38 12.93 29.14 12.19 6.192 < 0.001 
Age at 1st depression 35.93 12.68 32.55 11.75 5.041 < 0.001 
Current episode 
Duration 93.43 123.85 98.01 139.85 0.457 0.499 
Duration of (hypo)manic symptoms 12.19 46.59 11.15 22.63 0.073 0.788 
N of (hypo)manic symptoms 1.80 2.69 2.08 2.75 3.72 0.054 
Severity of mania 1.32 0.82 1.32 0.84 2.082 0.149 
Severity of depression 4.50 0.98 4.53 0.89 0.208 0.648 
Severity of BD 2.26 1.68 2.80 1.72 33.140 < 0.001 
Past episodes 
N of depressions 4.48 5.78 5.71 6.99 14.607 < 0.001 
Tot suicidal attempts 0.41 1.54 0.58 1.21 4.676 0.031 
Tot hospitalizations 1.72 3.98 1.52 3.01 0.962 0.327 
Past year 
N of mood episodes 2.12 3.94 2.99 6.66 13.130 < 0.001 
Tot days depressed 107.94 96.14 120 96.00 5.854 0.016 
Tot days (hypo)manic 12.24 39.94 20.21 43.57 13.573 < 0.001 













































reatment with mood stabilizers (OR = 1.50), current treat- 
ent with atypical antipsychotics (OR = 1.48), affective 
ability with previous AD treatments (OR = 1.44), current 
ffective lability (OR = 1.38) (see Supplementary Material 
able S2). 
. Discussion 
n the present post-hoc analysis on a large sample of acutely
epressed patients recruited from a large multi-site study, 
ypersomnia showed a strong association with mixed fea- 
ures. 
Sleep alterations in depression positively relate to a 
orse course of illness ( Takaesu et al., 2017 ) and an in-
rease in suicidality ( Littlewood et al., 2018 ). More, sleep
lterations are amongst the top warning signs of suicide 
 Bernert et al., 2017a; 2017b ). While insomnia symptoms 
ave been commonly described in mood disorders and BD, 
ypersomnia is a significant but underexplored problem 
 Vieta et al., 2018a ; 2018b ). Recently, a positive asso-
iation between hypersomnia and suicidal behaviors has 
een reported ( Michaels et al., 2017 ). In our sample of
epressed subjects, as expected, sleep disturbances were Please cite this article as: A. Murru, G. Guiso and M. Barbuti et al., The
Results from a large, international, observational study, European Neuro
02.011 ostly prevalent ( N = 2514 of 2811, 89,4%). Among them,
3.2% presented insomnia during the index episode SLEEP −,
hile 16.8% was experiencing hypersomnia SLEEP + . SLEEP −
atients were more frequently at their first affective onset
r were diagnosed with unipolar depression, compared with 
LEEP + . Similar findings of high rates of insomnia have been
ound in major unipolar depression (approximately 90%), in- 
icative of initial diagnosis of depression and higher sever-
ty of symptoms ( Baglioni and Riemann, 2012 ). On the con-
rary, a diagnosis of BD was significantly more frequent in
he SLEEP + group, supporting previous data on the frequent
ccurrence of atypical features in bipolar depression, pre- 
iously described especially in BD type II ( Thase, 2007 ).
otably, in our sample we did not find differences in BD
ubtypes among the SLEEP + patients, in line with recent
nding pointing on the prevalence of hypersomnia in BD
ype I ( Kaplan and Williams, 2017 ). According to the pri-
ary aim of the study, we focused on the SLEEP + subgroup
nd we found an overall higher severity of BD, higher num-
er of mood episodes, depressions, and higher numbers of
ays spent depressed and/or (hypo)manic compared with 
he SLEEP − group. The last finding is an unexpected result
ince hypersomnia is not contemplated as a manic or hy-
omanic symptom ( American Psychiatric Association, 2013 ).  implications of hypersomnia in the context of major depression: 
psychopharmacology, https://doi.org/10.1016/j.euroneuro.2019. 
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Table 3 Mixed specifiers and BD-related characteristics of the included sample. 
Sleep − ( n = 2091) Sleep + ( n = 423) 
Variables (YES) n % n % χ2 p 
DSM-5 mixed specifier 173 8.3 21 5.0 5.410 0.021 
RDC mixed specifier 577 27.6 139 32.9 4.790 0.029 
RDC mixed symptoms 
Psychomotor agitation 342 16.4 58 13.7 1.839 0.175 
Irritable mood 667 31.9 151 35.7 2.313 0.128 
Racing thoughts 221 10.6 64 15.1 7.281 0.007 
Affective lability 576 27.5 159 37.6 17.149 < 0.001 
More talkative/pressure to keep talking 236 11.3 52 12.3 0.351 0.553 
Distractibility 489 23.4 125 29.6 7.244 0.007 
Increased energy 139 6.6 27 6.4 0.040 0.842 
Aggression (verbal or physical) 286 13.7 62 14.7 0.283 0.595 
Hyperactivity 168 8.0 34 8.0 0.000 0.998 
Grandiosity 69 3.3 19 4.5 1.480 0.224 
Mood elation 91 4.4 20 4.7 0.118 0.731 
Impulsivity 275 13.2 71 16.8 3.913 0.048 
Risky behavior 163 7.8 21 5.0 4.156 0.041 
Hypersexuality 48 2.3 17 4.0 4.149 0.042 
Past treatments with ADs 
Past use of ADs 1662 79.5 361 85.3 7.685 0.006 
(Hypo)manic switches 319 15.3 102 24.1 19.799 < 0.001 
Resistance to treatment 566 27.1 145 34.3 9.018 0.003 
Mood lability 559 26.7 176 41.6 37.623 0.001 
Irritability 518 24.8 140 33.1 12.616 < 0.001 
Response unknown 151 7.2 31 7.3 0.006 0.938 


























































Specifically, our SLEEP + group positively related with past
mood elation, which in turn is traditionally associated with
insomnia or decreased need for sleep ( American Psychi-
atric Association, 2013 ; 2000 ). Our results, when confirmed
prospectively using a longitudinal design, could support the
hypothesis that insomnia and hypersomnia may and do occur
within the same illness course ( Kaplan and Williams, 2017 ). 
Several other findings from the present study seem to
support the association between hypersomnia and bipolar
diathesis, such as younger age at the first psychiatric symp-
toms and younger age at first depressive episode in the
SLEEP + group. These are among the most relevant clini-
cal indicators of unrecognized bipolarity in depressed pa-
tients ( Angst et al., 2012 ; 2010; Tondo et al., 2014 ). Also,
the higher frequency of both DSM-5 and RDC mixed specifier
during the index depressive episode in the SLEEP + group
points towards an association with bipolarity ( Iwanami
et al., 2015; McIntyre et al., 2015; Solé et al., 2017;
Takeshima and Oka, 2015 ). Yet, the DSM-5 specifier fails to
consider the possibility of an increased duration of sleep as
possible symptom of mixicity, potentially leaving aside pa-
tients that could very well fit into the group ( Pacchiarotti et
al., 2011; Popovic et al., 2016 ). 
With respect to treatment regimens, SLEEP + presented
significantly higher frequencies of mood stabilizers and
atypical antipsychotics use, coherently with the higher
BD prevalence Also, SLEEP + patients reported, in the
past, higher rates of antidepressant use, resistance, asso-
ciated (hypo)manic switches, and worsening of depression
(with affective lability, aggressiveness, chronicity), all thesePlease cite this article as: A. Murru, G. Guiso and M. Barbuti et al., The
Results from a large, international, observational study, European Neuro
02.011 factors being associated with bipolarity in our same sample
( Barbuti et al., 2017; Mazzarini et al., 2018; Verdolini et al.,
2017 ). This converges with past observations on the associa-
tion between hypersomnia and worse response to AD treat-
ment that call for specific therapeutic strategies ( Kaplan
and Williams, 2017; Verdolini et al., 2018 ). 
From a prognostic standpoint, SLEEP + group had a signif-
icant poorer outcome correlates expressed by higher rates
of comorbidities, especially with bulimia, OCD, social pho-
bia and GAD, higher rates of suicide ideation, compared
to SLEEP- and in line with previous studies ( Bernert et al.,
2017a ; 2017b; Michaels et al., 2017; ten Have et al., 2018;
van Krugten et al., 2018 ). Hence, hypersomnia is a relevant
target for early intervention strategies ( Vieta et al., 2018b ).
In our results, different significant findings in SLEEP + pa-
tients pointed at metabolic and weight-related features,
such as higher rates of comorbid eating disorders (i.e. binge
eating disorders, night eating and bulimia), and BMI from
overweight to obese. This significance persisted after lo-
gistic regression, as bulimia and BMI above normal signif-
icantly contributed as unique factors to the likelihood of
hypersomnia. These associations, together with the find-
ing of a bipolar diathesis in the SLEEP + group, outline a
possible shared susceptibility to BD and metabolic distur-
bances manifested as obesity/weight gain, in line with pre-
vious data ( Boudebesse et al., 2015 ). For these reasons, we
specifically studied the extreme phenotype of hypersom-
nia and overweight/obese (BMI > 25, above normal) pa-
tients. Indeed, this subgroup presented a clear overlap with
the whole SLEEP + population, presenting an even stronger implications of hypersomnia in the context of major depression: 
psychopharmacology, https://doi.org/10.1016/j.euroneuro.2019. 
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Table 4 Comorbid-related characteristics and treatments of the included sample. 
Sleep − ( n = 2091) Sleep + ( n = 423) 
Variables (YES) n % n % χ2 p 
Comorbidities 
Panic disorder 222 10.6 49 11.6 0.349 0.548 
OCD 87 4.2 32 7.6 9.072 0.002 
Social phobia 134 6.4 57 13.5 24.929 < 0.001 
GAD 358 17.2 98 23.2 8.667 0.003 
Eating disorders 124 6.0 57 13.7 30.9555 < 0.001 
Binge eating syndrome 40 1.9 25 6.0 22.721 < 0.001 
Anorexia 99 4.8 29 7.0 3.441 0.068 
Bulimia 20 1.0 25 6.1 49.939 < 0.001 
Night eating syndrome 46 2.2 23 5.5 14.099 < 0.001 
ADHD 45 2.2 12 2.9 0.776 0.378 
Borderline personality 136 6.5 27 6.4 0.009 1.000 
Alcohol abuse 
Use resulting in failure 104 5.0 17 4.0 0.706 0.401 
In hazardous situations 54 2.6 11 2.6 < 0.001 0.985 
Legal problems 21 1.0 3 0.7 0.327 0.568 
Continuous 48 2.3 13 3.1 0.890 0.345 
Never dependence 1330 63.8 253 60.0 2.220 0.150 
Substance abuse 
Use resulting in failure 33 1.6 4 0.9 0.975 0.504 
In hazardous situations 20 1.0 3 0.7 0.239 0.785 
Legal problems 6 0.3 3 0.7 1.755 0.185 
Continuous 43 2.1 8 1.9 0.047 1.000 
Never dependence 1326 63.6 262 62.2 0.281 0.596 
Treatments 
No treatment 234 11.2 43 10.2 0.377 0.609 
BZDs 978 46.8 190 44.9 0.486 0.485 
Other anxiolytics 85 4.1 15 3.5 0.248 0.618 
SSRIs 942 45.1 190 44.9 0.003 0.960 
SNRIs 388 18.6 79 18.7 0.003 0.954 
TCAs 386 18.5 72 17.0 0.489 0.484 
Other antidepressants 216 10.3 55 13.0 2.613 0.106 
Typical antipsychotics 216 10.3 51 12,1 1.105 0.293 
Atypical antipsychotics 463 22.1 144 34.0 27.203 < 0.001 
Mood stabilizers 544 26.0 169 40.0 33.633 < 0.001 
ECT 39 1.9 6 1.4 0.399 0.527 
Notes: OCD = Obsessive–Compulsive Disorder ; GAD = Generalized Anxiety Disorder ; ADHD = Attention Deficit Hyperactivity Disorder ; 
BZD = Benzodiazepine ; SSRI Selective Serotonin Re-Uptake Inhibitor ; SNRI = Serotonin and norepinephrine reuptake inhibitors ; 




























ssociation with mixicity and BD-related clinical and prog- 
ostic features, such as the use of BD treatments, poor re-
ponse to antidepressants and presence of affective lability. 
Last, in our study, the cumulative effects of risk fac-
ors for obesity and hypersomnia outlined a significant role 
f medications such as atypical antipsychotics and mood- 
tabilizers. The effect of these treatments on both in- 
reased sleep and appetite is well known ( Yatham et al.,
018 ), even though in our study is not preponderant. 
. Limitations 
lthough this study tried to provide clinical and prognos- 
ic information on the associations between hypersomnia, Please cite this article as: A. Murru, G. Guiso and M. Barbuti et al., The
Results from a large, international, observational study, European Neuro
02.011 besity and BD on a large sample of MDE patients, sev-
ral limitations can be highlighted. First, the cross-sectional 
esign of both the primary study and this post-hoc anal-
sis does not allow for causal inferences. Second, a con-
ounding effect is the greater use of medications strongly
elated with weight-gain and sedation such as atypical an-
ipsychotics and mood stabilizers, both in SLEEP + and hy-
ersomnia/overweight groups. Third, the sample of acutely 
epressed patients does not present an evaluation of eu-
hymic phases, neither in unipolar, nor in BD patients. More-
ver, we relied on the definition of sleep problems on the
asis of the absence/presence of the symptom, but we did
ot assessed total sleep hours, daytime sleepiness or delay
hase of sleep, that would have. Similarly, we did not em-
loy specific sleep questionnaires or objective instrumental  implications of hypersomnia in the context of major depression: 
psychopharmacology, https://doi.org/10.1016/j.euroneuro.2019. 
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Table 5 Final variables in the stepwise backward logistic regression model. 
B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Overweight-obese BMI 0.348 0.116 8.953 1 0.003 1.417 1.128 1.780 
Tot days DEP/last year 0.001 0.001 5.367 1 0.021 1.001 1.000 1.002 
Age at 1st DEP −0.018 0.005 12.510 1 0.000 0.983 0.973 0.992 
Lifetimes suicide attempts 0.266 0.131 4.151 1 0.042 1.305 1.010 1.686 
Current OCD 0.426 0.230 3.433 1 0.064 1.531 0.976 2.403 
Current social phobia 0.572 0.184 9.641 1 0.002 1.772 1.235 2.543 
Current bulimia 1.437 0.330 19.013 1 0.000 4.210 2.206 8.033 
Affective lability (past AD) 0.316 0.129 6.056 1 0.014 1.372 1.067 1.766 
Affective lability (current) 0.311 0.128 5.940 1 0.015 1.365 1.063 1.752 
Risky behaviors symptom −1.133 0.264 18.423 1 0.000 0.322 0.192 0.540 
Currently on AAP 0.306 0.130 5.582 1 0.018 1.359 1.054 1.752 
Currently on MS 0.288 0.132 4.786 1 0.029 1.334 1.030 1.726 
Notes: C.I. = Confidence Intervals. AAP = Atypical Antipsychotics ; AD = Antidepressants ; BMI = Body-Mass Index ; DEP = Depression ; 




















































sleep measurements, such as actigraphy and polysomnog-
raphy. Yet, the very definitions of insomnia and hypersom-
nia provide a univocal and objective, albeit clinical, esteem
of increased and decreased sleep, commonly observed from
the perspective of daily clinical practice. 
6. Conclusions 
The findings in the present post-hoc analysis outline the
important of hypersomnia as a negative factor in a major
depressive episode. Moreover, its strong link with bipolar
diathesis calls for its potential discriminative validity in the
differential diagnosis between unipolar and bipolar depres-
sion. Along with commonly used screeners for bipolarity,
excessive duration of night sleep represents an effective,
costless clinical feature to be taken into account in the di-
agnostic assessment of an acute depressive episode. 
The co-occurrence of hypersomnia and over-
weight/obesity might represent a more extreme clinical
phenotype of bipolarity complicated by treatment-related
adverse effects. BD patients presenting hypersomnia and
obese/overweight could benefit from an integrated ap-
proach aimed at reducing the impact of these risk factors
through the improvement of dietary habits, physical activ-
ity, sleep hygiene, lifestyle behaviors, along with tolerable
pharmacological treatments, in order to ameliorate their
illness course and outcome. 
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